期刊文献+

MUM1/IRF4在滤泡性淋巴瘤中的表达及其临床病理意义 被引量:7

MUM1/IRF4 expression in follicular lymphoma and its clinical and pathological significance
原文传递
导出
摘要 目的探讨MUM1/IRF4在滤泡性淋巴瘤(FL)中的表达情况及临床病理意义。方法对96例FL患者标本进行MUM1、CD10bcl-2、bcl-6、Ki-67免疫组织化学染色,并与患者的临床资料和病理学特征比较。结果MUMl在96例1FL中总的阳性率为59.2%(58/96),其中1~2级组阳性率为36.2%(19/51),3级组阳性率为86.4%(39/45)(χ2=24.406,P〈0.001)。68.9%伴有弥漫成分的FL患者MUM1阳性(χ2=-8.161,P=0.004)。MUM1和CD10的表达呈负相关,83.3%的CD10阴性病例表达MUM1(χ2=-12.649,P〈0.001)。MUM1阳性者核分裂和Ki-67标记指数高于MUM1阴性者(t=-3.852、t=-4.610,P〈0.001)。结论MUM1可作为FL分型的标志物。MUM1阳性的FL可能为类似非生发中心B细胞分化特征的高度恶性淋巴瘤。 Objective To clarify the MUM1/IRF4 expression in follicular lymphoma (FL) and its clinical and pathological significance. Methods Ninety-six cases FL were immunostained with MUM1, CDlc, bcl-2, bc1-6 and Ki-67 antibodies. The results were compared with their clinical and pathological features. Results The overall MUM1 expression rate in FL was 59.2 % (58/96), including 36.2 % (19/51) grade 1 or 2 and 86.4 %(39/45) grade 3 cases (X2 =24.406, P 〈0.001). 68.9 % cases with diffuse area were MUM1 positive (X2 =8.161, P =0.004). MUM1 and CD10 expression had inverse correlation, 83.3 % CD10 negative cases were MUM1 positive (X2= 12.649, P 〈0.001). The mitosis rate and Ki-67 label index were statistically higher in MUM1 positive cases than in negative cases (t = -3.852 & -4.610, respectively, P 〈0.001). Conclusion MUM1 can be used as a biomarker to divide FL into different malignancies. The MUM1 positive FL may be the feature of high grade non germinal center B cell malignant lymphoma.
出处 《白血病.淋巴瘤》 CAS 2011年第6期353-356,共4页 Journal of Leukemia & Lymphoma
基金 基金项目:首都医学科技发展基金(2009-2008) 北京希望马拉松专项基金(LC2007852)
关键词 淋巴瘤 滤泡型 MUM1/IFR4 免疫组织化学 Lymphoma, follicular MUM1/IFR4 Immunohistochemistry
  • 相关文献

参考文献16

  • 1Swerdlow SH, Campo E, Lee Harris N, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008, 220-228.
  • 2Gollub .W, Stassek B, Huckhagel T, et al. BCL 6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18) IgH/BCL2. Anticancer Res, 2009, 29: 4649-4656.
  • 3Montoto S, Davies A J, Mattbews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol, 2007, 25: 2426-2433.
  • 4Tsuboi K, Iida S, Inagaki H, et al. MUMI/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia, 2000,14: 449-456.
  • 5Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 2009, 5: 5494-5502.
  • 6Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol, 2010, 28: 2902-2913.
  • 7Karube K, Guo Y, Suzumiya J, et al. CD-10 MIAMI-follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood, 2007, 109: 3076-3079.
  • 8Mukhopadhyay S, Readling J, Cotter PD, et al. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Hum Pathol, 2005, 36: 571-575.
  • 9AI-Tourah A J, Gill KK, Chhanabhai M, etal. Population-based analysis of incidence and outcome of transformed non-Hodgkin's Iymphoma. J Clin Oncol, 2008, 26:5165-5169.
  • 10Martinez AE, Lin L, Dunphy CH. Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med. 2007, 131: 1084-1085.

同被引文献45

  • 1Takuya Watanabe.Treatment strategies for nodal and gastrointestinal follicular lymphoma:Current status and future development[J].World Journal of Gastroenterology,2010,16(44):5543-5554. 被引量:3
  • 2Masaya Iwamuro,Yoshinari Kawai,Katsuyoshi Takata,Seiji Kawano,Tadashi Yoshino,Hiroyuki Okada,Kazuhide Yamamoto.Primary intestinal follicular lymphoma:How to identify follicular lymphoma by routine endoscopy[J].World Journal of Gastrointestinal Endoscopy,2013,5(1):34-38. 被引量:4
  • 3唐曦,曾晓颖,张洪娣,陈玺,王静文.B细胞淋巴瘤老年患者的临床特征、生存和预后因素分析[J].肿瘤,2010,30(9):774-777. 被引量:3
  • 4陈愉,蔡庆发,吴炳绪,陈美燕,林雨冬,王星,赵彤.MUM1/IRF4在弥漫性大B细胞淋巴瘤中的表达及其意义[J].中国误诊学杂志,2007,7(10):2187-2189. 被引量:1
  • 5Finn WG. Kroft SH New classifications for non-Hodgkin's lymphoma[J]. Cancer Treat Res, 1999,99: 1-26.
  • 6Sehulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systemic review and meta-analysis[J]. J Natl Cancer Inst,2007,99:706-714.
  • 7Canioni D, Salles G, Mounier N, et al. High numbers of tumor associated macrophages have an adverse prognostic value that can be circumvented by rituximad in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trail[J]. J Clin Oncol, 2008,26: 440-446.
  • 8Hirt C, Schuler F, Kiefer T, et al. Rapid and sustained dearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t (14;18)PCR monitoring in advanced stage follicular lymphoma patients[J].Br J Haematol, 2008,141: 631-640.
  • 9Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without ritoximab during induction: results of a propective randomized phase Ⅲ intergroup trial[J]. Blood, 2006, 108 : 3295 3301.
  • 10Mclanghlin P, Hagemeister F B,Grillo-Lopez A J, et al. Rit uximab in indolent lymphoma: the single-agent pivotal trial [J]. Semin Oncol,1999,26(5 Suppl 14):79-87.

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部